Table 1. Baseline characteristics of the NSCLC study population.
| Parameter | % of non-missing values | |
|---|---|---|
| Median Age, years (Q1;Q3) | 66.4 (61.8; 72.1) | |
| Male Sex, N(%) | (n = 270) | |
| 210 | 78% | |
| Performance status | (n = 258) | |
| ECOG 0 | 48 | 19% |
| ECOG I | 196 | 76% |
| ECOG >II | 14 | 5% |
| Tumor stage | (n = 267) | |
| Stage I | 182 | 68% |
| Stage II | 58 | 22% |
| Stage III | 27 | 10% |
| Lymph nodes status | (n = 270) | |
| pN0 | 198 | 73% |
| pN1 | 55 | 20% |
| pN2 | 17 | 6% |
| Tumor histology | (n = 270) | |
| Squamous cell carcinoma | 123 | 46% |
| Adenocarcinoma | 107 | 40% |
| Large cell carcinoma | 40 | 15% |
| Tumor grading | (n = 265) | |
| Low grade (G1) | 6 | 2% |
| Intermediate grade (G2) | 91 | 34% |
| High grade (G3) | 168 | 63% |
| Expression of CD 13 (immunohistochemistry) | (n = 270) | |
| in stromal cells | 41 | 15% |
| in tumor cells | 20 | 7% |